Diabetes mellitus and stroke are two of the most consequential health problems worldwide. They also turn out to be deeply connected. People living with diabetes face a significantly higher chance of having a stroke, and when a stroke does occur, outcomes tend to be worse. Understanding why that connection exists, and whether any therapies can interrupt it, is the focus of a narrative review published in the journal Pharmaceutics.
The review zeroes in on a class of compounds called glucagon-like peptide-1 receptor agonists, commonly abbreviated GLP-1 RAs, as well as newer dual agonists that also activate the GIP receptor. These are incretin-based therapies, meaning they work through hormones that the gut releases after eating. Researchers have spent the past decade running large cardiovascular outcome trials on these compounds, and the data have started to reveal effects that go well beyond glucose control.
This article walks through what the review found, why the biology matters, and where the evidence is strong versus where researchers say more work is needed.
The diabetes-stroke connection
Diabetes does not cause stroke through a single mechanism. The review outlines several overlapping pathways that together raise cerebrovascular risk considerably. Chronically elevated blood glucose damages blood vessel walls, promotes inflammation, and accelerates the buildup of plaques inside arteries. This process, called atherosclerosis, narrows vessels and makes them more prone to blockage.
Diabetes also disrupts how blood clots form. Platelets, the small cell fragments that initiate clotting, become stickier and more reactive in a high-glucose environment. At the same time, the balance of clot-forming and clot-dissolving proteins shifts in a direction that favors clot formation. Add in high blood pressure, which is common in people with diabetes, and the stage is set for ischemic stroke, the type caused by a blocked artery cutting off blood flow to part of the brain.
The review emphasizes that worse outcomes after a stroke also trace back to these same mechanisms. Impaired blood flow regulation in small brain vessels, combined with systemic inflammation, can limit how well the brain recovers once a stroke has occurred.
What GLP-1 receptor agonists do
GLP-1 is a hormone that the small intestine releases in response to food. It signals the pancreas to release insulin in a glucose-dependent way, meaning the effect is stronger when blood sugar is high and weaker when it is low. This mechanism is part of why GLP-1 receptor agonists carry a relatively low risk of hypoglycemia compared with some older diabetes drugs.
Beyond the pancreas, GLP-1 receptors appear throughout the body, including in the heart, blood vessels, kidneys, and brain. When a GLP-1 receptor agonist binds those receptors, it can reduce inflammation, lower blood pressure, slow the heart rate slightly, and limit the progression of atherosclerosis. These are the effects that caught the attention of cardiovascular researchers and prompted the large outcome trials reviewed in this paper.
Dual agonists add a second target: the GIP receptor. GIP, or glucose-dependent insulinotropic polypeptide, is another gut hormone. Combining GLP-1 and GIP receptor activation appears to produce stronger effects on body weight and metabolic markers than either target alone. The review notes that this dual approach is still being evaluated for cerebrovascular-specific outcomes.
Evidence from large cardiovascular trials
The strongest evidence reviewed comes from large randomized trials designed primarily to assess cardiovascular safety and efficacy. Across multiple trials, GLP-1 RAs reduced the rate of major adverse cardiovascular events, a composite that typically includes heart attack, cardiovascular death, and stroke. The stroke component of that composite is what the review focuses on.
The review highlights that two specific agents, semaglutide and liraglutide, have shown the most consistent signals for reducing non-fatal stroke. Trial data suggest these compounds lowered stroke incidence, reduced related hospitalizations, and in some analyses were associated with better neurological outcomes in participants who had experienced a prior stroke.
However, the review is careful to note that not all GLP-1 RAs performed identically. Differences in how long each compound stays active in the body, how strongly it binds the receptor, and the characteristics of the patient populations enrolled all likely contribute to variation in results. The authors conclude that stroke reduction may be a class-level tendency rather than a guaranteed property of every agent in the group.
Emerging compounds and combinations
The review mentions several investigational compounds that may broaden future options. Among them is retatrutide, a triple agonist that targets the GLP-1, GIP, and glucagon receptors simultaneously. Early data on retatrutide have drawn research interest because of its pronounced effects on metabolic markers, though its specific cerebrovascular profile is still being characterized.
The review also references combination approaches such as cagrilintide paired with semaglutide, sometimes studied as a fixed combination, which targets both the GLP-1 receptor and the amylin receptor pathway. Orforglipron, an oral non-peptide molecule that activates the GLP-1 receptor, is noted as a potential future option for populations where injectable therapies present challenges.
The authors frame these compounds as promising additions to the research landscape rather than established therapies, emphasizing that cerebrovascular-specific trial data for most of them is limited or still being collected.
Acute stroke versus long-term prevention
One of the clearer conclusions in the review is a distinction between what GLP-1 RAs appear able to do over the long term versus what they can do in the immediate aftermath of a stroke. The long-term vascular risk reduction signal is well-supported by existing trial data. The question of whether these compounds offer meaningful neuroprotection in the acute setting, meaning the hours to days immediately after a stroke occurs, is much less settled.
Most of the evidence addressing acute stroke derives from early-phase trials or studies that are still ongoing at the time of the review. The authors specifically caution against interpreting preliminary signals as confirmed effects. Animal studies have suggested mechanisms through which GLP-1 receptor activation might limit brain injury after ischemia, but translating those findings to humans requires adequately powered randomized trials that have not yet been completed.
The practical takeaway from the review is that, based on current evidence, GLP-1 RAs are better understood as tools for reducing the probability of stroke over years rather than as acute interventions for managing stroke once it has started.
Gaps the researchers identified
The review closes by mapping out what is still unknown. Researchers do not yet have a clear picture of which patient subgroups are most likely to benefit from GLP-1 RA therapy in a cerebrovascular context. People with a history of prior stroke, those with specific metabolic profiles, or those in certain age ranges may respond differently, but the trial data have not been granular enough to answer those questions definitively.
The mechanisms behind any neuroprotective effects also require more investigation. The review notes that GLP-1 receptors are present in brain tissue and that several biological pathways, including reduced neuroinflammation and improved cerebral blood flow regulation, could theoretically explain a benefit, but these remain hypotheses in need of direct experimental confirmation in human populations.
Finally, the authors point to a need for longer follow-up periods in future trials. Cerebrovascular disease develops over decades, and studies designed to measure outcomes over one to five years may miss effects, or harms, that only emerge over a longer time horizon. The call for large, long-term, well-characterized studies runs throughout the review as its central research recommendation.
